Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "华东重机 客户名单 新加坡PSA DP World 2025"

Looking for quality documents?
external link icon
Repligen Acquires Bioprocessing Business of Refine Technology
- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., June 3, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has acquired the business of Refine Technology ("Refine"), including Refine's Alternating Tangential Flow ("ATF") System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen's bioprocessing business by adding a profitable and highly complementary product line while expanding the Company's direct sales presence worldwide. Repligen has entered into a definitive agreement effective June 2, 2014 to purchase Refine's business for a combination of $20.5 million in cash and 215,285 shares of Repligen common stock, for total upfront consideration of approximately $24.5 million.
external link icon
Repligen to Present at the 2013 Stephens Fall Investment Conference
WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the Stephens Fall Investment Conference on Wednesday, November 13 at 10:00 a.m. EST. The annual conference will take place November 12-13, 2013 at the New York Palace Hotel in New York. The Repligen presentation will not be webcast, however the slide presentation will be available on the Company's website at www.repligen.com ; see Events & Presentations under Investor Relations. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to
external link icon
Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. EDT. The conference will take place June 3-6 at the Grand Hyatt New York. The Repligen presentation will be webcast live and can be accessed through the Investors section of Company's website at www.repligen.com . The webcast and slide presentation will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a
external link icon
Repligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our
external link icon
Repligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2018 Global Healthcare Conference. The conference will take place on June 5-8 in New York City, and the Repligen presentation is scheduled for Wednesday, June 6 at 3:00 p.m. EDT. A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Participate in Stephens Inc. Fall Investment Conference 2016
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in Stephens’ Fall Investment Conference, being held November 8-9, 2016 in New York. Repligen President and CEO Tony J. Hunt, and CFO Jon Snodgres, will deliver a roundtable presentation on Tuesday, November 8 at 11:00 a.m.  Repligen’s current investor presentation is accessible through the Investor Events section of the Company’s website. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading manufacturer of
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen Forms Scientific Advisory Board
WALTHAM, Mass., March 31, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced its formation of a Scientific Advisory Board (“SAB”) to provide thought leadership and oversight of the Company’s innovation initiatives. The SAB will focus on expansion of Repligen’s bioprocessing product portfolio as well as identification and evaluation of new strategic opportunities. It is comprised of some of the world’s most recognized experts and trailblazers in the field of biopharmaceutical manufacturing.
Charles L. Cooney, Robert T. Haslam Professor of Chemical Engineering, Emeritus, of the MIT Department of Chemical Engineering, and Faculty Director, Emeritus, of the Deshpande Center for Technological Innovation, has been named the Chairman of the SAB. “As a vocal proponent of stimulating technological innovation in bioprocessing, I am enthused to be leading the SAB at Repligen,” said Dr. Cooney.
external link icon
Repligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will participate in the 14 th Annual Craig-Hallum Institutional Investor Conference, to be held in Minneapolis on Wednesday, May 31, 2017.
About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We